Drug Type Gene editing |
Synonyms STX 1200, STX1200 |
Target |
Action modulators |
Mechanism LPA modulators(Lysophosphatidic acid modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lipoprotein (a) hyperlipoproteinemia | Preclinical | United States | 01 May 2025 |